NasdaqGS - Nasdaq Real Time Price USD

BioAge Labs, Inc. (BIOA)

4.4500

+0.0100

+(0.23%)

At close: June 6 at 4:00:01 PM EDT

4.6799

+0.23

+(5.17%)

After hours: June 6 at 7:23:03 PM EDT

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced advances in its apeli

GlobeNewswire 5 days ago

BIOA
+0.23%
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity. The company plans to submit an Investigational New Drug (IND) application by mid-2025, with first Phase 1 single ascending dose (SAD) data expected by year-end. BGE-102, an internally discovered compound, is […]

Insider Monkey 10 days ago

BIOA
+0.23%
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonistsInternally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing EMERYVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product can

GlobeNewswire 10 days ago

BIOA
+0.23%
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–5, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, will

GlobeNewswire 12 days ago

BIOA
+0.23%
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic

GlobeNewswire last month

BIOA
+0.23%
With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest

Key Insights Institutions' substantial holdings in BioAge Labs implies that they have significant influence over the...

Simply Wall St. last month

BIOA
+0.23%
BioAge Labs, Inc. (BIOA): A Bull Case Theory

We came across a bullish thesis on BioAge Labs, Inc. (BIOA) on Substack by Ragnarok Research. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc. (BIOA)’s share was trading at $3.87 as of April 17th. BioAge Labs (BIOA) represents a classic “cigarette butt” investment—an overlooked and beaten-down company that still has a […]

Insider Monkey last month

BIOA
+0.23%
Several Insiders Invested In BioAge Labs Flagging Positive News

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. 2 months ago

BIOA
+0.23%
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic disea

GlobeNewswire 2 months ago

BIOA
+0.23%
BioArctic receives Orphan Drug Designation for exidavnemab the US

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.

PR Newswire 2 months ago

BIOA
+0.23%

BRCTF
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in B

GlobeNewswire 3 months ago

BIOA
+0.23%
BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

BioPharma Dive 4 months ago

BIOA
+0.23%

AKRO

VNDA
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, including a target identification collaboration with Novartis and a newly announced antibody therapeutics development collaboration with Lilly ExploR&D RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("B

GlobeNewswire 4 months ago

BIOA
+0.23%
After an obesity stumble, BioAge reconnects with its longevity pipeline

The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.

Pharma Voice 4 months ago

BIOA
+0.23%

NVS
BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BioAge Labs, Inc. (BIOA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 5 months ago

BIOA
+0.23%
BioAge and Novartis seek drug targets for ageing-related diseases

BioAge will receive an upfront payment and research funding of up to $20m.

Pharmaceutical Technology 5 months ago

BIOA
+0.23%

NVS
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical c

GlobeNewswire 5 months ago

BIOA
+0.23%
3 closely watched drugs that failed in the clinic

How recent setbacks and scattered successes could impact various sectors of the industry.

Pharma Voice 5 months ago

BIOA
+0.23%

ABBV
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.

Clinical Trials Arena 5 months ago

BIOA
+0.23%

LLY
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

On Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in collaboration with Eli Lilly And Co’s (NYSE:LLY) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025. The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. STRIDES is a Phase

Benzinga 5 months ago

BIOA
+0.23%

LLY

Performance Overview

Return	BIOA	S&P 500 (^GSPC)
YTD	-23.14%	+2.02%
1-Year	-80.22%	+12.09%
3-Year	-80.22%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioAge Labs, Inc. (BIOA)

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest

BioAge Labs, Inc. (BIOA): A Bull Case Theory

Several Insiders Invested In BioAge Labs Flagging Positive News

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

BioArctic receives Orphan Drug Designation for exidavnemab the US

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

After an obesity stumble, BioAge reconnects with its longevity pipeline

BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BioAge and Novartis seek drug targets for ageing-related diseases

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

3 closely watched drugs that failed in the clinic

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

Performance Overview